Shanghai Cancer Center
Shanghai, 200032, China
NCT Number: NCT07272109
The purpose of this study is to evaluate the efficacy of anti-diabetic treatment on improving the overall survival for metastatic pancreatic cancer patients complicated by diabetes receiving gemcitabine and nab-paclitaxel chemotherapy.
Trial opening soon.
Get Notified18 year–80 year
All sexes
Interventional
Phase 3
Shanghai, 200032, China
About 80% of patients with pancreatic adenocarcinoma have aberrant fasting blood glucose at the time of diagnosis. The consistent association between pancreatic cancer and diabetes mellitus has long been recognized and even been termed as "chicken and egg". Many reports have found that pancreatic cancer can result in diabetes, which is called type 3c diabetes. New-onset diabetes is commonly observed in pancreatic cancer patients and has been considered as a potential screening sign. Moreover, diabetes has been found as a predictor of poor outcome in pancreatic cancer.
Pancreatic cancer cells have a strong dependence on glucose and they are well-known for their sweet teeth. High glucose is associated with impaired immunologic reaction, intolerability to chemotherapy, radiotherapy and other major treatments, an increased risk of pancreatic surgery. Given the linkage between pancreatic cancer and diabetes or high blood glucose, a clinical trial is needed to validate the effect of anti-diabetic treatment in type 3c diabetes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
120 mg per square meter of body-surface area on days 1, 8, and 15 every 4 weeks
(1000 mg per square meter) on days 1, 8, and 15 every 4 weeks
Metformin, insulin or other anti-diabetic treatments
Attend follow-ups at designated endocrinology clinics, with proactive inquiry about hypoglycemic measures and medication implementation.
Time frame: 2 months
Time from randomization to death from any cause
Time frame: 2 months
Time from enrollment to first tumor progression.
Time frame: One month
Changes in fasting blood glucose levels.
Time frame: One month
Changes in glycated hemoglobin compared to baseline.
Time frame: One month
Changes in CA19-9, CEA, and CA125 levels compared to baseline
Contact information is provided by the study sponsor or research team.
Fudan University
Other
Active Anti-diabetic Treatment Plus Chemotherapy for Metastatic Pancreatic Cancer Related Diabetes Mellitus (Type 3c)
Acronym: PTCA199-16
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07736612
Digestive System Diseases, Digestive System Neoplasms
Hangzhou, Zhejiang, China
View Trial DetailsNCT06893276
Digestive System Diseases, Digestive System Neoplasms
Miami, Florida, United States
View Trial DetailsNCT07713823
Digestive System Diseases, Digestive System Neoplasms
View Trial DetailsNCT07325214
Borderline Resectable Pancreatic Cancer, Digestive System Diseases
Boston, Massachusetts, United States
View Trial Details